E
Carmanah Minerals Corp. CARM
CNSX
Recommendation
Sell
Prev Close
$0.03
Volume
--
Avg Vol (90D)
81,733
Market Cap
$1.09M
Dividend & Yield
--
52-Week Range
$0.015 - $0.065
P/E (TTM)
--
EPS (TTM)
-$0.0178
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
2/19/2025 - GuruFocus
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
2/19/2025 - PR Newswire
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
2/5/2025 - GuruFocus
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
2/5/2025 - PR Newswire
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $4.94 Average Target Price from Analysts
2/3/2025 - Ticker Report
Brokerages Set Carisma Therapeutics, Inc. (NASDAQ:CARM) Target Price at $4.94
1/9/2025 - Ticker Report
Barclays PLC Increases Stock Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM)
1/3/2025 - Ticker Report
Carisma Therapeutics Appoints Interim VP of Finance
12/26/2024 - TipRanks Financial Blog
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Rating of and#8220;Hold" by Analysts
12/17/2024 - Ticker Report
Carisma Therapeutics just downgraded at H.C. Wainwright, here's why
12/16/2024 - The Fly
Carisma investors should 'stay the course,' says D. Boral Capital
12/12/2024 - TipRanks Financial Blog
Carisma Therapeutics downgraded to Neutral from Outperform at Baird
12/12/2024 - TipRanks Financial Blog
Carisma Therapeutics just downgraded at Baird, here's why
12/12/2024 - The Fly
Carisma Therapeutics: Hold Rating Amid Strategic Shift and Uncertain Pipeline Prospects
12/12/2024 - TipRanks Financial Blog
Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI
12/11/2024 - TipRanks Financial Blog
Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI
12/11/2024 - The Fly
Carisma Therapeutics (CARM) Receives a Hold from Evercore ISI
12/11/2024 - TipRanks Financial Blog
Carisma Therapeutics (NASDAQ:CARM) Rating Lowered to Neutral at BTIG Research
12/11/2024 - Ticker Report
Carisma Therapeutics (NASDAQ:CARM) Given New $12.00 Price Target at D. Boral Capital
12/10/2024 - Ticker Report
Carisma Therapeutics just downgraded at BTIG, here's why
12/9/2024 - The Fly
Carisma Therapeutics price target lowered to $12 from $24 at D. Boral Capital
12/9/2024 - TipRanks Financial Blog
Carisma Therapeutics price target lowered by $12 at D. Boral Capital, here's why
12/9/2024 - The Fly
Penn spinout Carisma Therapeutics to narrow RandD focus, lay off more than a third of its workforce
12/9/2024 - Bizjournals.com - Health Care News
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
12/9/2024 - GuruFocus
Carisma Therapeutics announces restructuring, 34% workforce reduction
12/9/2024 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$467.20K
EBIT (TTM)
-$864.90K
Net Income (TTM)
-$880.20K
Balance Sheet
Total Assets (Q)
$58.30K
Total Debt (Q)
$0.00
Total Liabilities (Q)
$65.30K
Book Value Per Share (Q)
-$0.0001
Cash Flow
Cash from Operations (TTM)
-$42.30K
Cash from Investing (TTM)
-$71.20K
Cash from Financing (TTM)
$19.60K
Net Change in Cash (TTM)
-$93.90K
Filings
Filing Date
Monday, January 6, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
End of September (est)
Price History
Loading...
Beta
-0.69
7-Day Total Return
0.00%
30-Day Total Return
25.00%
60-Day Total Return
25.00%
90-Day Total Return
66.67%
Year to Date Total Return
-16.67%
1-Year Total Return
-16.67%
2-Year Total Return
-44.44%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Jul 19, 2024 - $0.015
52-week High
May 08, 2024 - $0.065
Valuation
Market Cap
$1.09M - Nano Cap
Enterprise Value
$1.09M
Price/Sales (TTM)
--
Price/Book (Q)
-300.00
Dividends and Shares
Shares Outstanding
52.95M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
carmanahcorp.ca
Phone Number
604 716 1036
Address
1111 Melville Street
Vancouver, BC V6E 3V6
Country
Canada
Year Founded
2020
Business Description
Sector
Materials
Industry
Materials
Carmanah Minerals Corp. engages in the exploration and evaluation of mineral properties in Canada. It explores for uranium, rare earth element, critical element, and precious metal deposits. The... more
Weiss Ratings